Lipitz S, Ben-Rafael Z, Dor J, Shalev J, Elenbogen A, Levran D, Serr D M, Mashiach S
Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Gynecol Obstet Invest. 1989;28(1):31-4. doi: 10.1159/000293495.
This study compared three groups of patients treated with three different protocols of suppression of the pituitary-ovarian axis prior to and during gonadotropin stimulation for in vitro fertilization with a nonsuppressed control group. Patients treated with daily injections of DTRp6 (Decapeptyl 0.5 mg) or with a single injection of Decapeptyl depot (3.2 mg CR) had a longer folicular phase than patients treated with Buserelin (1.2-1.5 mg daily) and the patients in the control group. The number of human menopausal gonadotropin ampules required to reach adequate stimulation was also significantly higher in the former two groups of patients. The number of oocytes recovered (6-7 per patient), fertilized (45-58%) and cleaved (92-100%) did not differ among the groups. Peak estradiol levels and the pregnancy rate were highest in the group treated with Buserelin. The overall picture would indicate that suppression with Buserelin was the least profound.
本研究比较了三组患者,这三组患者在促性腺激素刺激体外受精之前及期间采用三种不同的垂体 - 卵巢轴抑制方案进行治疗,并与未抑制的对照组进行比较。每日注射DTRp6(曲普瑞林0.5毫克)或单次注射长效曲普瑞林(3.2毫克控释剂)治疗的患者,其卵泡期比使用布舍瑞林(每日1.2 - 1.5毫克)治疗的患者及对照组患者更长。在前两组患者中,达到充分刺激所需的人绝经期促性腺激素安瓿数量也显著更高。各组回收的卵母细胞数量(每位患者6 - 7个)、受精率(45 - 58%)和卵裂率(92 - 100%)没有差异。布舍瑞林治疗组的雌二醇峰值水平和妊娠率最高。总体情况表明,布舍瑞林的抑制作用最不显著。